Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04685304 · ClinicalTrials.gov registry record · NA
Pharmacogenomics Applied to Chronic Pain Treatment in Primary Care
A NA study of Chronic Pain, sponsored by Medstar Health Research Institute.
- Active
- Registry status
- NA
- Development phase
- 315
- Enrollment target
- 1
- Study location
NCT04685304: Active NA study of Chronic Pain, sponsored by Medstar Health Research Institute.
NCT04685304 is a NA study of Chronic Pain that is active but no longer recruiting, run by Medstar Health Research Institute. The registered enrollment target is 315 participants, below the 771-participant average among 301 other Chronic Pain trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04685304, a NA study of Chronic Pain, is active but no longer recruiting, sponsored by Medstar Health Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 315 participants
- Enrollment target
- 1
- Study location
Study Summary
Pharmacogenomics (PGx) Applied to Chronic pain Treatment in primary care (PGx-ACT) is an open-label, prospective, randomized trial. Participants prescribed a relevant opioid and meet additional eligibility criteria will be randomized into either a PGx-guided care (intervention) arm or standard care (control) arm. The investigators will test the hypothesis that patients with intermediate or poor CYP2D6 metabolism assigned to PGx-guided care arm will experience improved pain control at 3 months compared to patients in the standard care arm. Additionally, the study investigators will be evaluating non-pain related uses of PGx information in the chronic pain population.
Conditions Studied
Interventions
- GENETIC Pharmacogenetic Testing
- OTHER Pharmacist Consultation Note
- OTHER Delayed pharmacogenetic testing
Study Locations (1)
Maryland
- MedStar Good Samaritan Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2024-04-11 |
| Phase | NA |
What the registry record for NCT04685304 still lists
NCT04685304 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 771-participant average among 301 other Chronic Pain trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 3 interventions - of which Pharmacogenetic Testing is the first listed.
NCT04685304 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04685304 about?
NCT04685304 is a clinical study titled "Pharmacogenomics Applied to Chronic Pain Treatment in Primary Care". Pharmacogenomics (PGx) Applied to Chronic pain Treatment in primary care (PGx-ACT) is an open-label, prospective, randomized trial. Participants prescribed a relevant opioid and meet additional eligibility criteria will be randomized into either a PGx-guided care (intervention) arm or standard care ...
What is the current status of trial NCT04685304?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 315 participants. The study started on 2020-12-02. Estimated completion is 2024-04-11.
What conditions does trial NCT04685304 study?
This clinical trial studies the following conditions: Chronic Pain.
What interventions are being tested in trial NCT04685304?
The interventions under investigation include: Pharmacogenetic Testing (GENETIC), Pharmacist Consultation Note (OTHER), Delayed pharmacogenetic testing (OTHER).
Who is sponsoring clinical trial NCT04685304?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04685304 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04685304's enrollment target sits among peer trials
315 49th of 301 higher than 253 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Acceptability, Feasibility and Usability of Various Conversational Data Collection Software
RECRUITING · NA
-
Local Cerebral Oxygenation in Chronic Pain Patients Utilizing Spinal Cord Stimulation
RECRUITING · NA
-
Group Medical Visits and Chiropractic Care for Older Adults With Chronic Spine Pain
RECRUITING · NA
-
Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma
RECRUITING · NA
-
Group-based Integrative Pain Management in Primary Care Safety Net Clinics
RECRUITING · NA
-
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI